LX2020 explained

LX2020 is an experimental gene therapy for arrhythmogenic cardiomyopathy caused by mutations to the plakophilin-2 gene. It is delivered via adeno-associated virus and was developed by Lexeo Therapeutics.[1] [2] [3]

Notes and References

  1. Abstract 18583: Preclinical Efficacy and Safety of Intravenously Administered LX2020 Gene Therapy for the Treatment of Arrhythmogenic Cardiomyopathy . Circulation . 2023 . 10.1161/circ.148.suppl_1.18583 . Sheikh . Farah . Zhang . Jing . Gutierrez Lara . Erika . Do . Aryanne . Nguyen . Lena . Bradford . William H. . Nair . Anju . Selvan . Nithya . Gutierrez . Sonia . Law . Ken . Fenn . Tim . Khanna . Richie . 148 . 266416146 .
  2. Sheikh . Farah . Zhang . Jing . Wang . Jie . Bradford . William H . Nair . Anju . Fargnoli . Anthony . Selvan . Nithya . Gutierrez . Sonia . Law . Ken . Fenn . Tim . McCormac . Paul . Barth . Jay A . Khanna . Richie . Abstract 13599: LX2020, an Adeno Associated Viral-Based Plakophilin 2 Gene Therapy Stabilizes Cardiac Disease Phenotype in a Severe Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy . Circulation . 8 November 2022 . 146 . Suppl_1 . 10.1161/circ.146.suppl_1.13599 . 259475762 . en . 0009-7322.
  3. Argirò . Alessia . Ding . Jeffrey . Adler . Eric . Gene therapy for heart failure and cardiomyopathies . Revista Española de Cardiología (English Edition) . December 2023 . 76 . 12 . 1042–1054 . 10.1016/j.rec.2023.06.009. 37506969 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "LX2020".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.